ANNOUNCEMENT AND CALL FOR PAPERS
CLINAM 10/2017 Conference and Exhibition
European Global Summit for Cutting-Edge Medicine May 7 -10, 2017
Clinical Nanomedicine and Targeted Medicine - Witnessing
the Solutions and tackling the Hurdles of Nanomedicine
The Route from Nanoscience to Diagnosis, Therapy towards Precision Medicine
Welcome to the European Global Summit for Nanomedicine and Targeted Medicine 2017. The goal of the CLINAM Foundation is the same as ever: to contribute to the benefit of patients and society by exploring and translating leading edge technologies towards clinical application, with anemphasis on Nanomedicine, Targeted Medicine and personalization. The summit keeps its tradition to build bridges from the enabling technologies to clinical application for major and neglected diseases. There is broad support for this summit by more than 35 collaborating initiatives.
This is the 10th Summit of its kind. The CLINAM Foundation sees it appropriate using this Jubilee to present a programme with strong focus on the route of nanomedicine to successful clinical applications in targeted and precision medicine and related fields, to discuss critically common bottlenecks based on the 10-years’ experience of our broad international expert community.
Over the past 9 years, the CLINAM Summit developed to an exquisite worldwide unique event bringing together all stakeholders in Nanomedicine and Targeted Medicine. Based on recent groundbreaking achievements, the next meeting in May will focus on • cancer, • immunotherapy, and • the pathway to safe nanomedicines, to enable breakthroughs in successful clinical applications and • seeking a deeper understanding of interactions of medical nanomaterials with living organisms. Plenary sessions will highlight some of the last year’s most interest-charged fields. In addition, three Satellite Meetings are scheduled.
CLINAM will welcome again more than 500 participants from the community of Nanomedicine and Targeted Medicine. Last year brought together experts from 39 countries. The CLINAM Foundation has become the service provider for Nanomedicine and the Summit is concerted with activities in many closely related fields to provide the innovative amalgam for the further< development of precision-medicine and clinical nanomedicine to the benefit of patient and humankind. The preliminary programme will be available in January 2017. We all look forward to a fruitful 10th Summit.
2. Submission of Abstracts for Oral Papers and Posters
See below (under 7) how you can already today apply to speak in Basel next May at CLINAM. Submission time is from September 15 until March 10. Incoming abstracts will besides quality also be validated on a “first come” basis since the number of applications is huge. Of course, the highest quality is decisive!
3. Format of Summit 2017
There is a request from many participants that the CLINAM Meeting should have more plenary sessions. The foundation has followed this advice.
- During one day, there will be Critical Workshops in which all Stakeholders will debate the solutions and debate the hurdles to be tackled. In each workshop, there are slots for up to 24 Speakers. Short statements and discussion, well divided in to topic blocks, are issue of these sessions led by veterans in the field and report assistants. These Workshop- Rapporteurs present in the plenary session the results to discuss and to define for the first time the Basel Theses on Nanomedicine. The focus of the workshops will be • Industries View, • Investors View, • Regulatory View, • Political View • Investigations View in Immunotherapy • Safety und Toxicity • Materials experts View • Characterization expert’s view.
- The plenary sessions will focus as in other years on main topics such as • Theranostics, • Pharmacokinetics, • Pharmacogenetics, • Cardiology and Atherosclerosis, • Brain Disorders, • Drug Hypersensitivity in the immune system, as well as on • inflammation and infection. We will also present • late breaking and ongoing trials and hot results of drugs and devices in Phase 3.
- Alongside the Plenary Sessions, there will be “Room-Debates” in which smaller groups will share “in depth discussions” in defined fields and state about their research, concepts, and progress. This allows great interaction also for participants that do not give an official talk.
- The Exhibition will give manifold possibilities to discuss concepts, devices, tools and processes regarding Cutting Edge Medicine.
4. The Tracks and Topics of the Conference
Track 1: Clinical Nanomedicine and Targeted Medicine – Basic Research
• Disease Mechanisms and Personalized Medicine • Regenerative Medicine • Novel Therapeutic and Diagnostic Approaches • Active and Passive Targeting • Targeted Delivery • Nano-Toxicology
Track 2: Clinical Nanomedicine and Targeted Medicine – Translation
• Unsolved Medical Problems • Precision Medicine and Theranostic Approaches • Regenerative Medicine • Late Breaking and Ongoing Clinical Trials • Applied Nanomedical Diagnostics and Therapeutics
Track 3: Enabling Technologies
• Nanomaterial Analytics and Testing • Molecular Profiling for Research and Efficacy/Toxicology Testing (Genomics, Proteomics, Glycomics, Lipidomics, Metabolomics) • Functional Testing Assays and Platforms • Single Cell Analyses • Cell Tracking • Stem Cell Biology and Engineering Technologies • Microfluidics • Tissue Engineering – Tissues-on-a-Chip – Bio-printing • In vivo Testing • Novel Imaging Approaches • Medical Devices
Track 4: Regulatory and Societal Affairs, Networking and Financing
• Regulatory Issues in Nanomedicine • Strategy and Policy • The Patient’s Perspective • Ethical Issues in Nanomedicine • University Village Presentations • Cutting-Edge EU-Project Presentations • Networking for International Consortium Formation • Venture Funding, Fund Investment and Business-Angel-Investments
5. The Exhibition as Mirror of the Conference
For the previous CLINAM Summits the number of exhibitors permanently increased. Exhibitors can profit of the possibility to meet a large community of target visitors on one single spot in Basel during the Summit. The CLINAM Summit is becoming one of the leading places for the pulse of the market and early sales in the field of cutting-edge nanomedicine.
6. Call for Papers – Topics
The CLINAM- Summit has usually more than 150 presentations. Many young, skilled researchers, starting entrepreneurs, engineers and scientists apply for posters and oral presentations. CLINAM invites all professionals active in the field of Clinical Medicine, Engineering, Industry, Venture, related Scientific Fields, scientists from academia and industry, political decision makers and regulatory authorities to submit abstracts for papers and posters in the following fields:
Nanomedicine and targeted medicine for cardiovascular disease, rheumatic disease, oncology, gastro-intestinal/hepatic disease, bacterial infection, viral infection, parasitic infection, implantology, inflammation, hematology, diabetes, neurology, neurosurgery, orphan diseases, eye and ear disease, tuberculosis, HIV, Ebola, tissue repair, orthopedics, …etc.
Nanosystems, nanoparticles, nanoanalytics and diagnostics, toxicology, nano-imaging, targeted drug delivery, using nanoparticles, GMP and quality assurance, propositions for solving a medical problem in a novel way by the use of nanotechnology, novel concepts and ideas if they can be supported by thorough reasoning and could lead to novel research and solutions. Materials for use in nanotechnology and targeted medicine, concepts, diagnosis and therapy in the field of personalized medicine: clinical diagnosis and management on the individual patient's clinical signs and symptoms, medical and family history, and data from laboratory and imaging evaluation to diagnose and treat illnesses, genetic testing leading to more personalized treatments. Also relevant novel tools for translational research and diagnostics are of high interest, etc..
Implications of Nanomedicine for society, developing countries, environment, risks and benefits, public health finance, health economics, and other subjects, etc.
4 Strategy, Government and Political Topics:
Strategy building and policy processes in nanomedicine. Strategic approaches towards establishing a unified funding area for nanotechnologies for medical research. Policy processes to foster leadership in Nanomedicine, regulatory authority topics as well as financial and marketing matters.
Industry projects and solutions in nanomedicine and targeted medicine, tools related to Nanomedicine and targeted medicine. Industry models for the Future large-scale production, Good Manufacturing Practice, etc.
Integrated interventions of exhibitors that are of scientific or technical high relevance and do not have the solely the purpose of promoting the trademark. All abstracts must cover original research aimed at future or current applications of nanoscience and targeted medicine including clinical trial designs, reports of ongoing and completed clinical trials, preclinical work, and technology papers with clinical long-term vision. All fields leading to the development of personalized medicine (precision-medicine) are also issues of great interest.
7. Abstract Submission (Sending Paper Abstract / Poster Abstract, Procedure)
Paper- or Poster-Abstract
Send us your paper- or poster- abstract, (Microsoft Word, RTF, or Open document file format, using Times New Roman, font size 11, single spacing NO PDF). The submission must not be longer than three pages, including metadata and figures (one figure is obligatory). All illustrations, figures, and tables must be placed within the text at the appropriate points.) Index your file as follows: Last name First name.abstract17.docx (or RTF etc.)
Please add in your mail as separate document s CV, max one page. No more than 5 titles of recent publications can be included Last name. First name.CV17.docx (or RTF etc.)
Send us a head picture (in gif or jpg 300-600 dpi and no copy paste!) Index your file as follows: Last name.First.Name.Picture17.jpg (or Gif)
8. Decision for Acceptance
Decision for Acceptance or Declination of Oral Presentations by will be given by March 30; 2017.You will then receive Decision-Letter that has to be answered within 5 days. Then, you have to register according to your category within one week. If you submitted your paper for oral presentation and it was not accepted, you are eligible for a Poster. In this case after receiving the Decision letter you have to accept or to refrain this option.
9. University Village 2017 and Small Speeches
The University Village is an exquisite forum for universities and research institutes, giving them opportunity to present themselves as well as novel approaches, new research projects and initial outcomes of research, and patents. Researchers and engineers can use the foyer to install exhibition stands booths as one-stop-shops for the large spectrum of conference participants. Poster presenters and University Village members are eligible for presentations in a special session of Small Speeches, 3 minutes in length and serving to highlight the research activities in Nanotechnology and Targeted Medicine. They must comprise three slides, • Slide 1: general introduction to the topic • Slide 2: some of the highlights of submitters' work and institutions' work • Slide 3: the proof as to how the work fits into the area of Nanomedicine including a glimpse into the future. Application for Small Talk Sessions is possible any time after acceptance of your poster in writing.
10. Registration Fees (online only)
11. Exhibition Fees (online only)
12. The Scientific Committee of the CLINAM Summit 2017
• Prof. Dr. med. Patrick Hunziker, University Hospital Basel (CH) (chairman) • Prof. Dr. med.Christoph Alexiou, University Hospital Erlangen (D) • Prof. Dr. Lajos Balogh, AA Nanomedicine and Nanotechnology Consultants, North Andover, American Society for Nanomedicine, Boston (USA) • Prof. Dr. Gerd Binnig, Nobel Laureate, Munich (D) • Prof. Dr. Yechezkel Barenholz, Hebrew University, Hadassah Medical School, Jerusalem (IL) • Prof. Dr. med. Omid Farokhzad, Associate Professor, Laboratory of Nanomedicine and Biomaterials, Harvard Medical School and Brigham and Women's Hospital, (USA) • Prof. Dr. med. Dong Soo Lee, PhD., Department of Nuclear Medicine, Seoul National University Seoul (KOR) • Dr. med. h.c. Beat Löffler, MA CLINAM-Foundation, Basel (CH) • Prof. Dr. Jan Mollenhauer, Lundbeckfonden Center of Excellence NanoCAN, Odense (DK) • Prof. Dr. med. Marisa Papaluca Amati, European Medicines Agency, London (UK) • Prof. Dr. Gert Storm, Institute for Pharmaceutical Sciences, Utrecht University, (NL) • Prof. Dr. Viola Vogel, Laboratory for Biologically Oriented Materials, ETH, Zürich (CH)
13. The Collaborators of the European Global CLINAM Summit
Congress Center Basel, Messeplatz 21, 2058 Basel 2nd Floor, Switzerland, Phone +41 58 206 28
14. Some Reasons to Attend CLINAM 10 /2017
- Highlight your achievements in a global event of huge reputation in front of the pioneers and opinion leaders from academia, industry, and regulatory bodies.
- Network with peers and pioneers in this unique encounter of the nanomedicine and targeted medicine community.
- Learn how to progress from an idea to a proof of concept an industrial product and achieve regulatory approval.
- Meet the big pharma players to discuss their view to Nanomedicine and to discuss their present pathways in which nano, as size, is evident but not declared under the label of Nanomedicine.
- Meet the regulators to ask directly your questions, declare your needs and make part of the harmonization process of regulatory matters. (The regulators need input to assist to facilitate the pathways in Nanomedicine to co-further the market.
- Pinpoint with the experts novel materials and approaches that might provide the future breakthroughs for patients.
- Discuss the state-of-the-art and future routes in safety requirements and nanotoxicology.
- Learn from new views in the cutting edge immunotherapy and reprogramming T-Cells and about CRISPR and about the stunning potential of this new branch of precision medicine.
- What are new targeting routes? How do we measure and get the quantification of actual drug delivery? By what concepts and means is drug delivery improvable? What are besides cancer drugs the 24 disease fields in which nanobased drugs and devices are existing or in the development pipeline?
- Discuss the long-term concept in regenerative medicine and the relation between the feasible and the ethics behind.
- Use CLINAM as your platform of excellence to develop your global trust building own network